Notable
BEXERA · Bexmarilimab + Azacitidine Versus Placebo + Azacitidine · Treatment-naïve Higher-risk Myelodysplastic Syndromes
Primary endpoint(s) modified
Also in this update: Recruitment opened; Trial sites expanded: 0 → 35 locations
Faron Pharmaceuticals LtdPhase 2 NCT07672769 Registry history of NCT07672769 on ClinicalTrials.gov (opens the registry)